Method of selecting individualized brain cancer therapy

A method of selecting a brain cancer therapy for a patient in need thereof and treating a patient susceptible to brain cancer, wherein the method comprises:

• a) assessing the expression level of PME-1 in a sample obtained from said patient;
• b) selecting a brain cancer therapy for a patient in need thereof based on the expression level of PME-1 in the sample obtained in step a) compared to a corresponding non-malignant tissue,
• wherein increased PME-1 expression indicates that said patient is not susceptible to monotherapy with a staurosporine (STS) derivative, but said patient is susceptible to a combination therapy with the STS derivative and a PME-1 silencing agent,
• wherein intact PME-1 expression indicates that said patient is susceptible to glioma therapy with a STS derivative;
• and
• c) administering a brain cancer monotherapy or combination therapy selected in step b) to said patient,
• wherein said monotherapy in step c) is at least one STS derivative without a PME-1 silencing agent,
• wherein said combination therapy in step c) is simultaneously, sequentially, or separately of at least one STS derivative and the PME-1 silencing agent to said patient susceptible to brain cancer therapy,
• wherein said PME-1 silencing agent is a siRNA, and
• wherein said siRNA is at least one selected from the group consisting of SEQ ID NO:
• 1, SEQ ID NO:
• 2, and SEQ ID NO:
• 3,
• wherein said STS derivative has the general Formula (I):
• wherein
• R′ is H or alkyl,
• R1 and R2 are H or together form oxo;
• R3 and R4 are independently H, OH or together form oxo;
• R5, R6, R6′, and R8 are independently selected from the group consisting of H, alkyl, alkoxy, hydroxy, hydroxylakyl, alkoxycarbonyl, or mono- and dialkylamino;
• R7 is selected from the group consisting of H, alkyl, alkoxy, hydroxy, hydroxylakyl, alkoxycarbonyl, or mono- and dialkylamino and N-methyl benzamide;
• X is CH2 or O;
• and
• n is 0 or 1.